EHA 2017 | Is gilteritinib the new breakthrough in the treatment of FLT3-mutated AML?
Mark Levis, MD, PhD, from John Hopkins University, Baltimore, MD, USA, presents us with an insight on how gilteritinib, a next-generation FLT3 inhibitor, is superior over previous FLT3 inhibitors in treating FLT3-mutated acute myeloid leukemia (AML). He also details the difficulty in quantifying responses from patients with relapsed FLT3-mutated AML who have been treated with a single agent, but adds that his team have developed an assay using next-generation sequencing that has allowed them to overcome these issues. He concludes with a statement on the recent retrieval of Phase I/II trial data (NCT02014558) focused on the study of gilteritinib in treating FLT-mutated AML and adds that the drug is now undergoing Phase III trials. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
